Bio Korea 2026 Kicks Off with Spotlight on Oligonucleotides

Why It Matters

The approvals and trial launches signal accelerating commercialization of novel neuro‑psychiatric and oncology therapies, reshaping market dynamics and investor interest in precision medicine platforms.

Key Takeaways

• Axsome's Auvelity gains FDA approval for Alzheimer’s agitation treatment
• Sonire launches U.S. Sunrise II study of HIFU system Suizenji
• Series A funding of $18 million supports Sonire’s cancer HIFU development
• Summit’s ivonescimab bispecific antibody advances to NSCLC Phase III trial

Pulse Analysis

The FDA’s endorsement of Axsome Therapeutics’ Auvelity marks a rare regulatory win for an agitation‑focused indication in Alzheimer’s disease. While most recent approvals target disease‑modifying pathways, Auvelity’s rapid‑acting mechanism addresses a high‑unmet‑need symptom, potentially opening a new revenue stream for neuro‑psychiatric drugmakers. Analysts will watch post‑approval uptake closely, as payer coverage and real‑world effectiveness data will determine whether the therapy can capture a sizable share of the $10 billion Alzheimer’s market.

Sonire Therapeutics’ initiation of the Sunrise II trial underscores growing confidence in high‑intensity focused ultrasound (HIFU) as a non‑invasive oncology tool. Backed by an $18 million Series A infusion, the Suizenji platform aims to ablate tumors with precision while sparing surrounding tissue, a proposition that could disrupt conventional surgery and radiation. If early safety and efficacy signals hold, Sonire may attract strategic partnerships or acquisition interest from larger med‑tech firms seeking to broaden their interventional oncology portfolios.

Summit Therapeutics’ progression of ivonescimab into a Phase III NSCLC study reflects the industry’s shift toward bispecific antibodies that simultaneously engage multiple tumor targets. The drug pairs an immune‑checkpoint inhibitor with a tumor‑associated antigen, promising enhanced anti‑cancer activity. Success in the pivotal trial could position Summit as a key player in the competitive lung‑cancer space, where blockbuster sales exceed $20 billion annually. Collectively, these developments illustrate how biotech firms are leveraging innovative modalities—small molecules, HIFU, and bispecific antibodies—to capture market share in high‑growth therapeutic areas.